JPMorgan analyst Anupam Rama lowered the firm’s price target on Syndax (SNDX) to $33 from $40 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology group.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Syndax Pharmaceuticals: Q3 Earnings Call Highlights
- Syndax price target raised to $38 from $35 at UBS
- Strong Growth Potential and Market Expansion Justify Buy Rating for Syndax Pharmaceuticals
- Syndax Pharmaceuticals: Strategic Advancements and Growth Potential Reinforce Buy Rating
- Syndax price target raised to $22 from $19 at Barclays